Imaging Versus Cardiac Biomarker Monitored HER2 Directed Therapy in Patients With Breast Cancer

Launched by ODENSE UNIVERSITY HOSPITAL · Jun 3, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new way to monitor heart health in women with HER2-positive breast cancer who are receiving treatment. Typically, doctors use imaging tests to check how well the heart is functioning during treatment, but these tests can be time-consuming and expensive. The goal of this study is to find out if measuring certain blood markers (called biomarkers) can be a simpler and more efficient way to keep track of heart health instead of relying solely on imaging.

To participate in this trial, women must be over 18 years old, have non-metastatic HER2-positive breast cancer, and be scheduled to receive standard chemotherapy along with HER2-directed therapy, such as trastuzumab or pertuzumab. Participants should have a normal heart function as shown by specific tests and should not have certain heart or lung conditions. If eligible, participants can expect to have their heart health monitored using blood tests during their treatment, which might make the process easier for them compared to traditional imaging methods. This study is currently recruiting participants, and it's an important step toward improving care for patients undergoing this type of treatment.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with non-metastatic HER2 positive breast cancer
• • Scheduled for standard chemotherapy and HER2 directed therapy with trastuzumab +/- pertuzumab
• • Age \> 18 years
• • Sinus rhythm on ECG
• • NT-proBNP below125 pg/ml
• • Troponin below threshold limit value
• • LVEF \> 55% by MUGA scan or an echocardiogram
• Exclusion Criteria:
• • Contra indications for cardiac magnetic resonance imaging (CMRI)
• • Chronic obstructive pulmonary disease with FEV1 \<80 % of predicted